Annual Cash & Cash Equivalents
$44.47 M
-$36.91 M-45.35%
December 31, 2023
Summary
- As of February 7, 2025, PSTX annual cash & cash equivalents is $44.47 million, with the most recent change of -$36.91 million (-45.35%) on December 31, 2023.
- During the last 3 years, PSTX annual cash & cash equivalents has fallen by -$39.49 million (-47.04%).
Performance
PSTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$49.34 M
+$18.80 M+61.53%
September 30, 2024
Summary
- As of February 7, 2025, PSTX quarterly cash and cash equivalents is $49.34 million, with the most recent change of +$18.80 million (+61.53%) on September 30, 2024.
- Over the past year, PSTX quarterly cash and cash equivalents has increased by +$18.80 million (+61.53%).
Performance
PSTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PSTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -45.4% | +61.5% |
| 3 y3 years | -47.0% | -75.1% |
| 5 y5 years | +46.3% | - |
PSTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -78.4% | at low | -76.1% | -48.3% |
| 5 y | 5-year | -78.4% | at low | -76.1% | -48.3% |
| alltime | all time | -78.4% | -64.9% | -76.1% | -48.3% |
Poseida Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $49.34 M(+61.5%) |
| Jun 2024 | - | $30.55 M(-42.7%) |
| Mar 2024 | - | $53.30 M(+19.8%) |
| Dec 2023 | $44.47 M(-45.4%) | $44.47 M(+74.4%) |
| Sep 2023 | - | $25.50 M(-48.9%) |
| Jun 2023 | - | $49.91 M(+24.3%) |
| Mar 2023 | - | $40.14 M(-50.7%) |
| Dec 2022 | $81.38 M(-60.6%) | $81.38 M(-50.6%) |
| Sep 2022 | - | $164.81 M(+161.8%) |
| Jun 2022 | - | $62.96 M(-65.7%) |
| Mar 2022 | - | $183.49 M(-11.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $206.32 M(+145.7%) | $206.32 M(+4.3%) |
| Sep 2021 | - | $197.81 M(-0.9%) |
| Jun 2021 | - | $199.69 M(+17.6%) |
| Mar 2021 | - | $169.79 M(+102.2%) |
| Dec 2020 | $83.97 M(-4.3%) | $83.97 M(+26.7%) |
| Sep 2020 | - | $66.27 M(-55.0%) |
| Jun 2020 | - | $147.13 M(+132.5%) |
| Mar 2020 | - | $63.27 M(-27.9%) |
| Dec 2019 | $87.78 M(+188.8%) | $87.78 M |
| Dec 2018 | $30.39 M(+94.5%) | - |
| Dec 2017 | $15.63 M | - |
FAQ
- What is Poseida Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Poseida Therapeutics?
- What is Poseida Therapeutics annual cash & cash equivalents year-on-year change?
- What is Poseida Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Poseida Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PSTX is $44.47 M
What is the all time high annual cash & cash equivalents for Poseida Therapeutics?
Poseida Therapeutics all-time high annual cash & cash equivalents is $206.32 M
What is Poseida Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, PSTX annual cash & cash equivalents has changed by -$36.91 M (-45.35%)
What is Poseida Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PSTX is $49.34 M
What is the all time high quarterly cash and cash equivalents for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly cash and cash equivalents is $206.32 M
What is Poseida Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, PSTX quarterly cash and cash equivalents has changed by +$18.80 M (+61.53%)